The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Brain-specific expression of an exogenous gene after i.v. administration
Open accessAbstract
The treatment of brain diseases with gene therapy requires the gene to be expressed throughout the central nervous system, and this is possible by using gene targeting technology that delivers the gene across the blood–brain barrier after i.v. administration of a nonviral formulation of the gene. The plasmid DNA is targeted to brain with pegylated immunoliposomes (PILs) using a targeting ligand such as a peptidomimetic mAb, which binds to a transporting receptor on the blood–brain barrier. The present studies adapt the PIL gene targeting technology to the mouse by using the rat 8D3 mAb to the mouse transferrin receptor. Tissue-specific expression in brain and peripheral organs of different exogenous genes (β-galactosidase, luciferase) is examined at 1–3 days after i.v. injection in adult mice of the exogenous gene packaged in the interior of 8D3-PIL. The expression plasmid is driven either by a broadly expressed promoter, simian virus 40, or by a brain-specific promoter taken from the 5′ flanking sequence of the human glial fibrillary acidic protein (GFAP) gene. The transgene is expressed in both brain and peripheral tissues when the simian virus 40 promoter is used, but the expression of the exogenous gene is confined to the brain when the transgene is under the influence of the brain-specific GFAP promoter. Confocal microscopy colocalizes immunoreactive bacterial β-galactosidase with immunoreactive GFAP in brain astrocytes. These studies indicate that tissue-specific gene expression in brain is possible after the i.v. administration of a nonviral vector with the combined use of gene targeting technology and tissue-specific gene promoters.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. C., Lasic, D. D., & Redemann, C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.24.11460 · Cited by 1,620
Brain drug delivery of small molecules using immunoliposomes
Huwyler, J., Wu, D., & Pardridge, W. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14164 · Cited by 656
Self-citationGFAP promoter directs astrocyte-specific expression in transgenic mice
Brenner, M., Kisseberth, W., Su, Y., Besnard, F., & Messing, A. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-03-01030.1994 · Cited by 485
Pardridge, W. M., Kang, Y.-S., Buciak, J. L., & Yang, J. (1995) · Pharmaceutical Research · doi:10.1023/a:1016244500596 · Cited by 315
Self-citationDewey, R. A., Morrissey, G., Cowsill, C. M., Stone, D., Bolognani, F., Dodd, N. J. F., Southgate, T. D., Klatzmann, D., Lassmann, H., Castro, M. G., et al. (1999) · Nature Medicine · doi:10.1038/15207 · Cited by 311
Lee, H. J., Engelhardt, B., Lesley, J., Bickel, U., & Pardridge, W. M. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35388-1 · Cited by 287
Self-citationNoninvasive gene targeting to the brain
Shi, N., & Pardridge, W. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130187497 · Cited by 252
Self-citationBrain Drug Targeting: The Future of Brain Drug Development
Pardridge, W. M. (2001) · Cambridge University Press eBooks · doi:10.1017/cbo9780511549571 · Cited by 246
Self-citationColoma, M. J., Lee, H. J., Kurihara, A., Landaw, E. M., Boado, R. J., Morrison, S. L., & Pardridge, W. M. (2000) · Pharmaceutical Research · doi:10.1023/a:1007592720793 · Cited by 206
Self-citationBarry, M. E., Pinto-Gonzalez, D., Orson, F. M., McKenzie, G. J., Petry, G. R., & Barry, M. A. (1999) · Human Gene Therapy · doi:10.1089/10430349950016816 · Cited by 173
Shi, N., Boado, R. J., & Pardridge, W. M. (2001) · Pharmaceutical Research · doi:10.1023/a:1010910523202 · Cited by 156
Self-citationKissel, K., Hamm, S., Schulz, M., Vecchi, A., Garlanda, C., & Engelhardt, B. (1998) · Histochemistry and Cell Biology · doi:10.1007/s004180050266 · Cited by 133
Osaka, G., Carey, K. D., Cuthbertson, A. G. S., et al. (1996) · Journal of Pharmaceutical Sciences · doi:10.1021/js9504494 · Cited by 104
Lawrence, M. S., Foellmer, H. G., Elsworth, J. D., Kim, J. H., Léránth, C., Kozlowski, D. A., Bothwell, A. L. M., Davidson, B. L., Bohn, M. C., & Redmond, D. E. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300958 · Cited by 52
Differentiation-dependent expression of transgenes in engineered astrocyte cell lines
Segovia, J., Vergara, P., & Brenner, M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00042-1 · Cited by 35
Transport of recombinant CD4 through the rat blood-brain barrier in vivo.
Pardridge, W. M., Buciak, J. L., & Yoshikawa, T. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11135-x · Cited by 24
Self-citation(1998) · doi:10.1002/(sici)1098-1136(199805)23:1<1::aid-glia1>3.0.co;2-b
Cited by
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
“Nonviral plasmid DNA is encapsulated in pegylated liposomes, which are then targeted across the BBB and the brain cell membrane with peptidomimetic monoclonal antibodies that function as molecular Trojan horses.(65) The pegylated immunoliposome (PIL) nonviral gene transfer technology has enabled 100% normalization of…”
BackgroundSelf-citationProspects for cationic polymers in gene and oligonucleotide therapy against cancer
Merdan, T., Kopec̆ek, J., & Kissel, T. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00046-7 · Cited by 785
Delivery of therapeutic agents to the central nervous system: the problems and the possibilities
Begley, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.08.001 · Cited by 679
Lipid-based Nanoparticles for Nucleic Acid Delivery
Li, W., & Szoka, F. C. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9180-5 · Cited by 641
DNA-based therapeutics and DNA delivery systems: A comprehensive review
Patil, S. D., Rhodes, D. G., & Burgess, D. J. (2005) · The AAPS Journal · doi:10.1208/aapsj070109 · Cited by 630
Metadata
- Authors
- Shi, N., Zhang, Y., Zhu, C., Boado, R. J., & Pardridge, W. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2001-10-09
- Volume
- 98
- Issue
- 22
- Pages
- 12754-12759
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2055810294
- Cited by
- 273
- References
- 17
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.